-
June 28, 2012
As expected, regulators in the USA have given the green light to Arena Pharmaceuticals and Eisai's Belviq, making it the first obesity drug to be approved in 13 years
Full story
-
April 11, 2012
While Vivus' share price slid on the news that regulators in the USA have put back their final decision on Qnexa by three months, analysts at Cowen & Co are still confident of approval for the obesity drug
Full story
-
April 10, 2012
Vivus will have to wait a bit longer before getting US approval for its obesity drug Qnexa
Full story
-
March 09, 2012
Pharmaceutical companies should increase their investment in weight loss therapies to support the growing number of clinically obese individuals worldwide
Full story
-
March 02, 2012
Vivus, which has been the subject of frenzied takeover talk since advisors to the US Food and Drug Administration backed its obesity drug Qnexa, has launched a public offering aimed at raising $202.5 million.
Full story
-
February 23, 2012
It looks as though Vivus' Qnexa is set to be the first prescription diet drug to reach the US market since 1999 after advisors to the FDA overwhelmingly recommended the pill for approval
Full story
-
February 20, 2012
Documents released ahead of a US regulatory panel meeting for Vivus' Qnexa suggest that the obesity treatment may once again not be recommended for approval
Full story
-
October 18, 2011
After the successful conclusion of talks with the US Food and Drug Administration, Vivus has resubmitted its previously-rejected obesity treatment Qnexa for approval
Full story
-
April 05, 2011
Shares in Vivus were on the rise as investors celebrated clinical data indicating that the firm's obesity drug Qnexa reduced weight and improved cardiovascular profiles.
Full story
-
February 02, 2011
Orexigen Therapeutics' stock collapsed yesterday after US regulators turned away its weight loss drug Contrave, requesting a lengthy and expensive additional trial.
Full story